“Naloxone? Not for me!” First cross-assessment by patients and healthcare professionals of the risk of opioid overdose

Author:

Aquizerate Aurélie,Rousselet Morgane,Cochard Axel,Guerlais Marylène,Gerardin Marie,Lefebvre Emilie,Duval Mélanie,Laforgue Edouard-Jules,Victorri-Vigneau Caroline

Abstract

Abstract Background Opioid-related mortality is a rising public health concern in France, where opioids were in 2021 implicated in 75% of overdose deaths. Opioid substitution treatment (OST) was implicated in almost half of deaths related to substance and drug abuse. Although naloxone could prevent 80% of these deaths, there are a number of barriers to the distribution of take-home naloxone (THN) among opioid users in France. This study is the first one which compares patients' self-assessment of the risk of future opioid overdose with the hetero-assessment provided by healthcare professionals in a population of individuals eligible for naloxone. Methods This was a multicenter descriptive observational study carried out in pharmacies across the Pays de la Loire region (France) during April and May 2022. All adult patients who visited a participating pharmacy for a prescription of OST and provided oral informed consent were enrolled in the study. Retrospective data were collected through cross-sectional interviews conducted by the pharmacist with the patient, utilizing an ad hoc questionnaire. The patient’s self-assessment of overdose risk was evaluated using a Likert scale from 0 to 10. The pharmacist relied on the presence or absence of overdose risk situations defined by the French Health Authority (HAS). The need to hold THN was assessed using a composite criterion. Results A total of 34 patients were interviewed; near one third were aware of the existence of THN and a minority had THN in their possession. Out of the 34 participants, 29 assessed their own risk of future opioid overdose: 65.5% reported having zero risk, while 6.9% believed they had a high risk. Nevertheless, at least one risk situation of opioid overdose was identified according to HAS criteria in 73.5% of the participants (n = 25). Consequently, 55% of the participants underestimated their risk of experiencing a future opioid overdose. Yet, dispensing THN has been judged necessary for 88.2% of the participants. Conclusion This study underscored the imperative need to inform not only healthcare professionals but also the patients and users themselves on the availability of THN and the risk situations of opioid overdose.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous)

Reference50 articles.

1. Agence Nationale de Sécurité du médicament et des produits de santé. Etat des lieux de la consommation des antalgiques opioïdes et leurs usages problématiques. Saint Denis: ANSM; 2019 févr

2. Robert M, Jouanjus E, Khouri C, Fouilhé Sam-Laï N, Revol B. The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2023;118(4):771–5. https://doi.org/10.1111/add.16081.

3. Association Française des Centres d’Addictovigilance. Décès en Relation avec l’Abus de Médicaments Et de Substances n.d. http://www.addictovigilance.fr/drames (accessed October 29, 2021).

4. Revol B, Willeman T, Manceau M, Dumestre-Toulet V, Gaulier JM, Fouilhé Sam-Laï N, et al. Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES Register. JAMA Netw Open. 2023;6(8):e2331398.

5. HAS, Traitement du Trouble de l’Usage d’opioïdes, mars 2022 (in French) [Internet]. Disponible sur: https://www.has-sante.fr/upload/docs/application/pdf/2022-03/traitement_du_trouble_de_lusage_dopioides_-_fiche.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3